Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Gemtuzumab ozogamicin in frontline AML therapy

Juliette Lambert • 30 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies Gemtuzumab ozogamicin
ALFA 0701

Juliette Lambert, MD, Versailles Hospital, Le Chesnay, France, outlines the final efficacy and safety updates from the open-label, Phase III ALFA-0701 trial (NCT00927498) of gemtuzumab ozogamicin for de novo acute myeloid leukemia (AML). Additionally, Dr Lambert discusses the use of gemtuzumab ozogamicin in clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Juliette Lambert

1:36
Targeted therapy for AML
Juliette Lambert • 30 Jun 2020

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals